Results 61 to 70 of about 22,035 (254)

The structural, dynamic, and thermodynamic basis of darunavir resistance of a heavily mutated HIV-1 protease using molecular dynamics simulation

Frontiers in Molecular Biosciences, 2022
The human immunodeficiency virus type 1 protease (HIV-1 PR) is an important enzyme in the life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them into active proteins. Darunavir (DRV) suppresses the wild-type HIV-1 PR (
Yaser Shabanpour, Sharareh Sajjadi, Esmaeil Behmard, Parviz Abdolmaleki, Amir Homayoun Keihan   +4 more
doaj   +1 more source

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter [PDF]

, 2015
The SLC22A1 influx transporter is expressed on the basolateral membrane of hepatocytes and is involved in the excretion of numerous cations. Inhibition of SLC22A1 by several antiretrovirals, such as the protease inhibitor darunavir, has not previously ...
Liptrott, NJ, Moss, DM, Owen, A, Siccardi, M   +3 more
core   +2 more sources

Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens [PDF]

, 2017
López-Cortés, Luis F. et al.[Background and Objective] Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients that have not experienced ...
López-Cortés, Luis F., Pasquau-Liaño, Juan, Viciana, Pompeyo   +2 more
core   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

HIV Research & Clinical Practice, 2021
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Objective
Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups   +10 more
doaj   +1 more source

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial [PDF]

, 2015
This article has been accepted for publication in Clinical Infectious Diseases ©2014 The Authors .Published by Oxford University Press on Clinical Infectious Disease 60.5. DOI: 10.1093/cid/ciu898Background.
Aguilar, A., Antela, A., Arcaina, P., Arnaiz, J. A., Arnaiz, Juan A., Arribas, J. R., Asensi, V., Barrera, G., Beleta, H., Beleta, Helena, Bernardino, J. I., Bernardino, Jose I., Blanco, J. R., Cairó, M., Carton, Jose A., Cartón, J. A., Castro, J. M., Crespo, M., Curran, A., Curran, Adrià, Dalmau, D., Deulofeu, Ramon, Domingo, P., Domingo, Pere, Dronda, F., Ferrer, E., Ferrer, Elena, Garcia, D., Garcia, David, Gatell, J. M., Gatell, Jose M., Giner, L., Gonzalez-Cordon, Ana, González-Cordón, A., Gutierrez, Felix, Gutierrez, M., Gutiérrez, F., Lamas, A., Losada, E., Martinez, Esteban, Martí-Belda, P., Martínez, E., Masiá, M., Mateo, M. G., Moya, S., Murillas, J., Murillas, Javier, Negredo, E., Negredo, Eugenia, Padilla, S., Pampliega, M., Pejenaute, Andrea, Pejenaute, Andrea, Peraire, J., Peraire, Joaquim, Pich, J., Pich, Judit, Podzamczer, Daniel, Podzamczer, Daniel, Portilla, J., Portilla, Joaquin, Prieto, A., Puig, J., Pérez, I., Pérez, Ignacio, Ramos, J. R., Ramos, Nuria, Ramos, Nuria, Ribera, Esteban, Ribera, Esteban, Robledano, C., Rozas, N., Santos, I., Santos, Ignacio, Sanz, J., Saumoy, M., Vargas, M., Velli, P., Vidal, F., Viladés, C.   +79 more
core   +2 more sources

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Servicio de dispensación: interacción entre darunavir y quetiapina

Farmacéuticos Comunitarios, 2022
Paciente varón de 52 años, con síndrome metabólico, virus de inmunodeficiencia humana (VIH), insomnio, trastorno de ansiedad generalizada, esquizofrenia y con medicación analgésica, que viene sufriendo numerosos episodios nocturnos de insomnio e ...
Damià Barris Blundell , Octavio Carrasco Naranjo   +1 more
doaj   +1 more source

Darunavir does not prevent SARS-CoV-2 infection in HIV patients

Pharmacological Research, 2020
Graphical ...
A. Riva, F. Conti, D. Bernacchia, L. Pezzati, S. Sollima, S. Merli, M. Siano, Angelica Lupo, S. Rusconi, D. Cattaneo, C. Gervasoni   +10 more
semanticscholar   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source